Line 36: | Line 36: | ||
{{Heidelberg/templateus/Imagebox| | {{Heidelberg/templateus/Imagebox| | ||
https://static.igem.org/mediawiki/2017/7/76/T--Heidelberg--Team_Heidelberg_2017_Caffeine_3.png| | https://static.igem.org/mediawiki/2017/7/76/T--Heidelberg--Team_Heidelberg_2017_Caffeine_3.png| | ||
− | + | Figure 2: Chemical structure of caffeine| Caffeine is a substrate of CYP1A2 <x-ref>perera2010caffeine</x-ref>.| pos = left }} | |
{{Heidelberg/templateus/Imagebox| | {{Heidelberg/templateus/Imagebox| | ||
https://static.igem.org/mediawiki/2017/9/95/T--Heidelberg--Team_Heidelberg_2017_Theobromine_Praxanthin_Theophylline.png| | https://static.igem.org/mediawiki/2017/9/95/T--Heidelberg--Team_Heidelberg_2017_Theobromine_Praxanthin_Theophylline.png| | ||
− | + | Figure 3: Chemical structures of Paraxanthine, Theobromine and Theophylline | By N3 demethylation caffeine is metabolized into these three xanthine derivates by CYP1A2 <x-ref>perera2010caffeine</x-ref>.| pos = left }} | |
}} | }} | ||
Line 52: | Line 52: | ||
<h1>Experimental procedures</h1> | <h1>Experimental procedures</h1> | ||
{{Heidelberg/templateus/Imagebox|https://static.igem.org/mediawiki/2017/thumb/2/2d/T--Heidelberg--Team_Heidelberg_2017_CYP_dithinide_geschnitten_MK.png/349px-T--Heidelberg--Team_Heidelberg_2017_CYP_dithinide_geschnitten_MK.png| | {{Heidelberg/templateus/Imagebox|https://static.igem.org/mediawiki/2017/thumb/2/2d/T--Heidelberg--Team_Heidelberg_2017_CYP_dithinide_geschnitten_MK.png/349px-T--Heidelberg--Team_Heidelberg_2017_CYP_dithinide_geschnitten_MK.png| | ||
− | + | Figure 4: Test of CYP1A2 conformation by sodium dithionite| | |
After the addition of sodium dithionite to the E.coli cell lysate (expressing CYP1A2) a color change could be detected as the solution turned darker/brown. |pos = right | After the addition of sodium dithionite to the E.coli cell lysate (expressing CYP1A2) a color change could be detected as the solution turned darker/brown. |pos = right | ||
}} | }} | ||
Line 71: | Line 71: | ||
{{#tag:html| | {{#tag:html| | ||
<h1>Results</h1> | <h1>Results</h1> | ||
− | In a first step, we wanted to validate our AP. Therefore, we added theophylline with a concentration of 100 µM to our inoculated culture and performed two rounds of PREDCEL. Afterwards, we determined the phage titers by plaque assays. Our theophylline treated culture displayed approximately two times higher phage titers than the non-treated control culture | + | In a first step, we wanted to validate our AP. Therefore, we added theophylline with a concentration of 100 µM to our inoculated culture and performed two rounds of PREDCEL. Afterwards, we determined the phage titers by plaque assays. Our theophylline treated culture displayed approximately two times higher phage titers than the non-treated control culture . |
Using the same experimental conditions, but replacing the theophylline treatment by a 300 µM caffeine treatment, we verified the functionality of CYP1A2 and thus of our SP. If caffeine is added to the culture CYP1A2 catalyzes the reaction from caffeine to theophylline. The resulting increase of the theophylline concentration further activates the riboswitch on the AP and phage propagation is stimulated (Fig.5). | Using the same experimental conditions, but replacing the theophylline treatment by a 300 µM caffeine treatment, we verified the functionality of CYP1A2 and thus of our SP. If caffeine is added to the culture CYP1A2 catalyzes the reaction from caffeine to theophylline. The resulting increase of the theophylline concentration further activates the riboswitch on the AP and phage propagation is stimulated (Fig.5). | ||
}}}} | }}}} | ||
+ | {{Heidelberg/templateus/Imagebox|https://static.igem.org/mediawiki/2017/6/66/T--Heidelberg--Team_Heidelberg_2017_Bar_chart_2.png| | ||
+ | Figure 6: Bar chart| | ||
+ | Text | ||
+ | }} | ||
{{Heidelberg/templateus/Contentsection| | {{Heidelberg/templateus/Contentsection| | ||
{{#tag:html| | {{#tag:html| |
Revision as of 22:11, 1 November 2017
Cytochrome Engineering
Re-directing CYP1A2 product specificity
Introduction
Enzymes, i.e. proteins mediating specific, catalytic functions, are amongst the most powerful molecular machines invented by nature. Since decades, humans utilize naturally occurring enzymes as bio detergents (e.g. in washing powderThe engineering of novel enzymes catalyzing reactions that do not or only inefficiently occur in nature holds great promise for biotechnological production of regenerative fuel, biomaterials and novel pharmaceuticals, e.g. based on Organosilicons. However, so far, enzyme engineering has typically been a time-consuming, elaborate, expensive and inefficient process, usually requiring laborious, iterative trial-and-error optimization of engineered candidates
To accelerate the development of novel enzymes, our team harnessed the engineering strategy nature uses: Evolution.